Qiagen (NYSE:QGEN) Given Buy Rating at Goldman Sachs Group

Goldman Sachs Group reissued their buy rating on shares of Qiagen (NYSE:QGEN) in a research report sent to investors on Friday, Borsen Zeitung reports.

QGEN has been the topic of a number of other reports. Zacks Investment Research cut shares of Qiagen from a hold rating to a sell rating in a report on Monday, April 15th. Wolfe Research assumed coverage on shares of Qiagen in a research report on Thursday, May 30th. They set a peer perform rating for the company. UBS Group assumed coverage on shares of Qiagen in a research report on Friday, March 15th. They issued a neutral rating and a $42.00 price objective for the company. Finally, Deutsche Bank reaffirmed a buy rating on shares of Qiagen in a research report on Wednesday, May 8th. Five analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $42.00.

QGEN opened at $40.71 on Friday. Qiagen has a 1-year low of $32.33 and a 1-year high of $41.55. The company has a debt-to-equity ratio of 0.54, a current ratio of 1.69 and a quick ratio of 1.52. The company has a market capitalization of $9.18 billion, a price-to-earnings ratio of 30.38, a PEG ratio of 2.44 and a beta of 0.84.

Qiagen (NYSE:QGEN) last released its quarterly earnings results on Monday, May 6th. The company reported $0.27 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.01. The company had revenue of $348.70 million for the quarter, compared to the consensus estimate of $351.68 million. Qiagen had a net margin of 12.45% and a return on equity of 12.22%. Qiagen’s revenue was up 1.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.26 earnings per share. Equities research analysts anticipate that Qiagen will post 1.43 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. BB&T Securities LLC grew its stake in Qiagen by 7.0% in the fourth quarter. BB&T Securities LLC now owns 7,527 shares of the company’s stock valued at $259,000 after purchasing an additional 490 shares in the last quarter. Lindbrook Capital LLC acquired a new position in Qiagen in the 4th quarter valued at approximately $25,000. Toronto Dominion Bank grew its stake in shares of Qiagen by 71.9% in the 4th quarter. Toronto Dominion Bank now owns 27,004 shares of the company’s stock valued at $918,000 after purchasing an additional 11,294 shares during the period. LPL Financial LLC grew its stake in shares of Qiagen by 11.4% in the 4th quarter. LPL Financial LLC now owns 10,932 shares of the company’s stock valued at $377,000 after purchasing an additional 1,123 shares during the period. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. grew its stake in shares of Qiagen by 38.2% in the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 3,528 shares of the company’s stock valued at $119,000 after purchasing an additional 976 shares during the period. 63.22% of the stock is owned by hedge funds and other institutional investors.

About Qiagen

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.

See Also: Bollinger Bands

Analyst Recommendations for Qiagen (NYSE:QGEN)

Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.